NASDAQ$XENE
Xenon Pharmaceuticals Inc · Q4 2022 earnings
Q4 2022 earnings · · Investor relations
Briefing
Xenon Pharmaceuticals reported financial results for Q4 2022, highlighting the advancement of the XEN1101 Phase 3 epilepsy program and anticipated clinical milestones.
Xenon Pharmaceuticals reported no revenue for the fourth quarter of 2022. Research and development expenses were $34.8 million, and general and administrative expenses were $8.5 million, resulting in a net loss of $37.4 million. Cash and cash equivalents and marketable securities were $720.8 million as of December 31, 2022.
- XEN1101 Phase 3 epilepsy program continued to advance in focal onset seizures and primary generalized tonic clonic seizures.
- Topline data from XEN1101 Phase 2 X-NOVA clinical trial in major depressive disorder expected in third quarter.
- Cash and cash equivalents and marketable securities were $720.8 million as of December 31, 2022.
- Based on current operating plans, Xenon anticipates having sufficient cash to fund operations into 2026.
Headline financials
Revenue & EPS history
Xenon Pharmaceuticals · Revenue · Quarterly
$8.77K
Forward guidance
Xenon anticipates topline results from the XEN1101 Phase 2 X-NOVA study in major depressive disorder in the third quarter and data from Neurocrine's Phase 2 study in adult patients with focal onset seizures in the second half of the year. They also expect to complete the EPIK study in 2024.
Tailwinds
- Advancement of XEN1101 Phase 3 epilepsy program.
- Anticipated topline data from XEN1101 Phase 2 X-NOVA clinical trial in major depressive disorder in Q3.
- Data read-out from Neurocrine's Phase 2 study in adult patients with focal onset seizures expected in H2.
- Sufficient cash to fund operations into 2026.
- Ongoing X-TOLE Phase 2b OLE continues to generate important long-term data for XEN1101.
Headwinds
- Clinical trials may not demonstrate safety and efficacy of product candidates.
- Assumptions regarding planned expenditures and sufficiency of cash to fund operations may be incorrect.
- Product candidates may fail in development or not receive regulatory approvals.
- Regulatory agencies may impose additional requirements or delay clinical trials.
- The impact of the ongoing COVID-19 pandemic on research and clinical development plans and timelines and results of operations.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2022
-1.2%
Avg return
Earnings day
-1.4%
Avg return
5 days after
+0.8%
Avg return
30 days after
39%
19 / 49 earnings
Positive
+15.8%
Q2 2018
Best reaction
-17.5%
Q3 2017
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -4.5% | -6.1% | -11.8% | |
| Q4 2025 | -3.7% | -4.2% | +21.3% | |
| Q3 2025 | -4.9% | -7.0% | +8.5% | |
| Q2 2025 | +5.5% | +12.1% | +9.1% | |
| Q1 2025 | +2.3% | +0.7% | +5.7% | |
| Q4 2024 | -3.4% | -3.0% | -10.6% | |
| Q3 2024 | -4.8% | -9.6% | -10.5% | |
| Q1 2024 | -5.6% | -5.5% | -12.2% | |
| Q4 2023 | -2.1% | -3.8% | -10.0% | |
| Q3 2023 | -5.6% | -6.6% | +20.6% | |
| Q2 2023 | +8.6% | +6.2% | +7.9% | |
| Q1 2023 | -3.2% | -5.5% | +0.0% | |
| Q4 2022 | -5.3% | -5.9% | -9.3% | |
| Q3 2022 | -4.9% | -1.0% | +5.1% | |
| Q2 2022 | +0.1% | -4.4% | -3.3% | |
| Q1 2022 | +5.9% | +17.1% | +16.7% | |
| Q4 2021 | +3.3% | -4.6% | -3.6% | |
| Q3 2021 | -10.1% | -10.1% | -26.7% | |
| Q2 2021 | +6.3% | +5.6% | +3.9% | |
| Q1 2021 | -4.0% | -4.5% | +4.6% | |
| Q4 2020 | +8.2% | +6.6% | -4.2% | |
| Q3 2020 | -2.3% | +1.1% | -0.4% | |
| Q2 2020 | -2.1% | -3.6% | -1.9% | |
| Q1 2020 | +4.3% | -3.6% | -9.4% | |
| Q4 2019 | -9.3% | -18.7% | -10.3% | |
| Q3 2019 | +0.9% | -0.2% | +53.9% | |
| Q2 2019 | +0.6% | +4.0% | +10.2% | |
| Q1 2019 | -4.6% | -6.6% | +8.7% | |
| Q4 2018 | +7.3% | +6.3% | +18.8% | |
| Q3 2018 | -5.7% | -9.7% | -29.4% | |
| Q2 2018 | +15.8% | +23.7% | +38.4% | |
| Q1 2018 | +0.0% | -1.7% | +5.0% | |
| Q4 2017 | +6.2% | +17.3% | +22.2% | |
| Q3 2017 | -17.5% | -22.2% | -25.4% | |
| Q2 2017 | -4.8% | -7.9% | +1.6% | |
| Q1 2017 | -2.4% | -1.2% | -7.1% | |
| Q4 2016 | +0.0% | +0.0% | -54.2% | |
| Q3 2016 | -2.5% | -1.3% | -0.6% | |
| Q2 2016 | +1.5% | +3.6% | +9.6% | |
| Q1 2016 | +0.7% | — | — | |
| Q4 2015 | -1.1% | — | — | |
| Q3 2015 | -1.7% | — | — | |
| Q2 2015 | -6.0% | — | — | |
| Q1 2015 | +0.7% | — | — | |
| Q4 2012 | +6.1% | — | — | |
| Q3 2014 | +6.1% | — | — | |
| Q4 2014 | -5.5% | — | — | |
| Q3 2013 | -9.7% | — | — | |
| Q4 2013 | -9.7% | — | — | |
| Q1 2014 | — | — | — | |
| Q2 2013 | — | — | — | |
| Q1 2013 | — | — | — | |
| Q3 2012 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro